Keywords: sucampto, gains, canada, rights, rescula, usa-based, sucampo

Sucampto gains US Canada rights for Rescula

Article | 24 April 2009

USA-based Sucampo Pharmaceuticals has licensed commercialization rights from Japan's R-Tech Ueno to Rescula (unoprostone isopropyl) in the USA and Canada, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Rescula

Unoprostone isopropyl

Go to drug listing